Ameliorating effect of erythropoietin in a severe case of COVID-19: case report

The COVID-19 pandemic is arguably one of the greatest public health crises since the 1918 influenza pandemic. Although several vaccines have been approved and rolled out, effective antiviral treatment options are very limited. Here, we present a case of severe COVID-19 that failed to respond to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Maufak, Mais Mamoon, Khan, Gulfaraz, Purushothaman, Ani, Ahamed, Fiaz, Jallo, Mahir Khalil, Rizwan, Muhammad, Kumar, Sangeeth, Almansouri, Ahmed, Almansoori, Taleb Mohamed, Ouseppachen, Megha Thottappillil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883794/
https://www.ncbi.nlm.nih.gov/pubmed/36762166
http://dx.doi.org/10.11604/pamj.2022.43.129.35014
_version_ 1784879582639292416
author Maufak, Mais Mamoon
Khan, Gulfaraz
Purushothaman, Ani
Ahamed, Fiaz
Jallo, Mahir Khalil
Rizwan, Muhammad
Kumar, Sangeeth
Almansouri, Ahmed
Almansoori, Taleb Mohamed
Ouseppachen, Megha Thottappillil
author_facet Maufak, Mais Mamoon
Khan, Gulfaraz
Purushothaman, Ani
Ahamed, Fiaz
Jallo, Mahir Khalil
Rizwan, Muhammad
Kumar, Sangeeth
Almansouri, Ahmed
Almansoori, Taleb Mohamed
Ouseppachen, Megha Thottappillil
author_sort Maufak, Mais Mamoon
collection PubMed
description The COVID-19 pandemic is arguably one of the greatest public health crises since the 1918 influenza pandemic. Although several vaccines have been approved and rolled out, effective antiviral treatment options are very limited. Here, we present a case of severe COVID-19 that failed to respond to the standard interventions and continued to deteriorate. On day 22 of his illness, after informed consent, the patient was administered 4000IU of erythropoietin (EPO) subcutaneously, in the hope of improving his O(2) saturation. Positive response was observed in the patient within 24 hours. This prompted us to continued EPO treatment for a total of 42 days until full recovery and discharge. Our findings warrant further studies to ascertain the use of EPO in severe cases COVID-19.
format Online
Article
Text
id pubmed-9883794
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The African Field Epidemiology Network
record_format MEDLINE/PubMed
spelling pubmed-98837942023-02-08 Ameliorating effect of erythropoietin in a severe case of COVID-19: case report Maufak, Mais Mamoon Khan, Gulfaraz Purushothaman, Ani Ahamed, Fiaz Jallo, Mahir Khalil Rizwan, Muhammad Kumar, Sangeeth Almansouri, Ahmed Almansoori, Taleb Mohamed Ouseppachen, Megha Thottappillil Pan Afr Med J Case Report The COVID-19 pandemic is arguably one of the greatest public health crises since the 1918 influenza pandemic. Although several vaccines have been approved and rolled out, effective antiviral treatment options are very limited. Here, we present a case of severe COVID-19 that failed to respond to the standard interventions and continued to deteriorate. On day 22 of his illness, after informed consent, the patient was administered 4000IU of erythropoietin (EPO) subcutaneously, in the hope of improving his O(2) saturation. Positive response was observed in the patient within 24 hours. This prompted us to continued EPO treatment for a total of 42 days until full recovery and discharge. Our findings warrant further studies to ascertain the use of EPO in severe cases COVID-19. The African Field Epidemiology Network 2022-11-09 /pmc/articles/PMC9883794/ /pubmed/36762166 http://dx.doi.org/10.11604/pamj.2022.43.129.35014 Text en Copyright: Mais Mamoon Maufak et al. https://creativecommons.org/licenses/by/4.0/The Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Maufak, Mais Mamoon
Khan, Gulfaraz
Purushothaman, Ani
Ahamed, Fiaz
Jallo, Mahir Khalil
Rizwan, Muhammad
Kumar, Sangeeth
Almansouri, Ahmed
Almansoori, Taleb Mohamed
Ouseppachen, Megha Thottappillil
Ameliorating effect of erythropoietin in a severe case of COVID-19: case report
title Ameliorating effect of erythropoietin in a severe case of COVID-19: case report
title_full Ameliorating effect of erythropoietin in a severe case of COVID-19: case report
title_fullStr Ameliorating effect of erythropoietin in a severe case of COVID-19: case report
title_full_unstemmed Ameliorating effect of erythropoietin in a severe case of COVID-19: case report
title_short Ameliorating effect of erythropoietin in a severe case of COVID-19: case report
title_sort ameliorating effect of erythropoietin in a severe case of covid-19: case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883794/
https://www.ncbi.nlm.nih.gov/pubmed/36762166
http://dx.doi.org/10.11604/pamj.2022.43.129.35014
work_keys_str_mv AT maufakmaismamoon amelioratingeffectoferythropoietininaseverecaseofcovid19casereport
AT khangulfaraz amelioratingeffectoferythropoietininaseverecaseofcovid19casereport
AT purushothamanani amelioratingeffectoferythropoietininaseverecaseofcovid19casereport
AT ahamedfiaz amelioratingeffectoferythropoietininaseverecaseofcovid19casereport
AT jallomahirkhalil amelioratingeffectoferythropoietininaseverecaseofcovid19casereport
AT rizwanmuhammad amelioratingeffectoferythropoietininaseverecaseofcovid19casereport
AT kumarsangeeth amelioratingeffectoferythropoietininaseverecaseofcovid19casereport
AT almansouriahmed amelioratingeffectoferythropoietininaseverecaseofcovid19casereport
AT almansooritalebmohamed amelioratingeffectoferythropoietininaseverecaseofcovid19casereport
AT ouseppachenmeghathottappillil amelioratingeffectoferythropoietininaseverecaseofcovid19casereport

Ejemplares similares